Swedish Study Supports Mammography Screening for Women Age 40 to 49

News
Article
OncologyONCOLOGY Vol 10 No 5
Volume 10
Issue 5

Areview of major clinical trials strongly supports the value of mammography screening for women in their 40s. The review showed a 24% decrease in deaths from breast cancer among women who underwent screening mammograms compared to

Areview of major clinical trials strongly supports the value ofmammography screening for women in their 40s. The review showeda 24% decrease in deaths from breast cancer among women who underwentscreening mammograms compared to women who were not screened.

Results of the review were released at an international conferenceunder the auspices of the Swedish Cancer Society and the SwedishNational Board of Health and Welfare in Falun, Sweden.

The findings from Sweden strongly support the recommendation ofmore than 20 US medical and women's organizations for regularmammographic screening of women in the 40- to 49-year-old group.Among those groups are the American College of Radiology, theAmerican Cancer Society, the National Alliance of Breast CancerOrganizations, the Y-ME National Breast Cancer Organization, TheKomen Foundation, the American Medical Association, and the AmericanCollege of Obstetricians and Gynecologists.

Included in the study were seven regional clinical trials fromfive Swedish cities, one in Scotland, and a major clinical trialin New York City.

In the studies, screening was done every 2 years. If such screeningwere done annually, the decrease in deaths would likely be asmuch as 35%, said Dr. Stephen A. Feig, professor of radiologyat Jefferson Medical College in Philadelphia and a nationallyrecognized expert on screening mammography.

Dr. Feig, who is also a member of the ACR Task Force on BreastCancer, also pointed out that the impressive 22% decrease wasrecorded without the benefit of the more advanced mammographymachines used today. Therefore, he said, "we can really expectto see an even greater impact of screening in the future."

Recent Videos
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
According to John Henson, MD, “What we need are better treatments to control the [brain] tumor once it’s detected.”
First-degree relatives of patients who passed away from pancreatic cancer should be genetically tested to identify their risk for the disease.
Destigmatizing cancer care for incarcerated patients may help ensure that they feel supported both in their treatment and their humanity.
A lower percentage of patients who were released within 1 year of incarceration received guideline-concurrent care vs incarcerated patients.
A collaboration between the Connecticut Departments of Health and Corrections and the COPPER Center aimed to improve outcomes among incarcerated patients.
Computational models help researchers anticipate how ADCs may behave in later lines of development, while they are still in the early stages.
ADC payloads with high levels of potency can sometimes lead to higher levels of toxicity, which can eliminate the therapeutic window for patients with cancer.
Related Content